Conduct of Research Activities. During the Research Term and subject to the JSC's and JRC's review and, as applicable, approval of each Research Plan, the Parties will use Commercially Reasonable Efforts to perform (themselves or through their Affiliates or subject to Section 4.2, permitted subcontractors) the Research Plan Activities in accordance with the applicable Research Plan until the Development Candidate Selection Date for a Research Compound for such Research Target. NVS will have the option, in its sole discretion, to extend the Research Term for [***] period (the original Research Term plus such [***] period, the "Extended Research Term"). In the event that NVS desires to exercise such option, it shall provide Pliant with written notice to that effect at least [***] days prior to the end of the Research Term. If a Party anticipates that material Research Plan Activities under the applicable Research Plan will not have been completed by the end of the Extended Research Term, such Party may so notify the other Party at least [***] days prior to the end of the Extended Research Term, in which case the Parties will discuss in good faith the process for completing such Research Plan Activities and the extension of the Research Term for a further [***] period following the Extended Research Term (a "Second Extension"). For clarity, neither Party will be obligated to agree to a Second Extension, and if the Parties do not agree in writing to a Second Extension prior to the date upon which the Extended Research Term would otherwise expire, the Research Term shall expire upon the date of expiration of the Extended Research Term. In performing its respective Research Plan Activities, each Party: (a) will conduct such activities in a good scientific manner, in compliance with all Applicable Law in all material respects, including, where applicable, cGMP, cGLP, cGCP, and current international regulatory standards; and (b) will not employ or use any Debarred Person. [***]
Conduct of Research Activities. Each Party shall diligently perform or cause to be performed its Research Activities in good scientific manner and in compliance in all material respects with all Applicable Laws, including good laboratory practice and good clinical practices to the extent applicable.
Conduct of Research Activities. During the Research Term and subject to the JSC’s and JRDC’s review and, as applicable, approval of each Research Plan, the Parties will use Commercially Reasonable Efforts to perform (themselves or through their Affiliates or subject to Section 3.3(b) permitted subcontractors) the Research Plan Activities in accordance with the applicable Research Plan and the timelines set forth therein to achieve selection of a Research Compound with respect to a Target as a Development Candidate. On a Target-by-Target basis, the Research Program will begin on [***], and end upon the earlier of (i) the date of selection by Novartis of a DC with respect to such Target pursuant to Section 2.4 (the “Development Candidate Selection Date”), and (ii) [***] after the Effective Date (the “Calendar Term”), which period may be extended by mutual written agreement of the Parties (the “Research Term”). In performing its respective Research Plan Activities, each Party: (a) will conduct such activities in a good scientific manner, in compliance with all applicable Law in all material respects, including, where applicable, cGMP, cGLP, cGCP, and current international regulatory standards; and (b) will not employ or use any Debarred Person.
Conduct of Research Activities. Each Party shall (a) perform or cause to be performed the Research Activities in good scientific manner and in compliance in all material respects with all Applicable Laws, and [(b) use skilled personnel up to an equivalent of [ ] FTE of the level of a [ ] to perform such Research Activities][Note: the resources to be applied can be set out here or in the Research Plan or Research Budget.]. Neither Party guarantees that a particular result can be obtained. As between the Parties, the UK Company shall direct the activities of the Lancaster Student.
Conduct of Research Activities. Sponsor and both Institutions shall: (a) perform or cause to be performed the Research Activities in good scientific manner and in compliance with Applicable Laws, (b) pursue the objectives of the Research Plan efficiently and expeditiously by allocating sufficient time, effort, equipment and skilled personnel to complete such activities diligently and promptly, and (c) if the Research Activities involve the use of animals, the Research Activities shall be conducted in accordance with Company’s Global Policy on Bioethics, which can be found at: which can be found by clicking the “Resources” tab on the same may be amended from time to time. This policy defines the principles, behaviours and ethical standards governing Company’s research and development activities worldwide.
Conduct of Research Activities. Subject to the JRC’s review and approval of any amendments to the Research Plan, the Parties will use [***] to perform (or subject to Section 2.7 (Subcontractors), have their permitted subcontractors perform) the Research Plan Activities in accordance with the Research Plan. In performing its respective Research Plan Activities, each Party: (a) will conduct such activities in a good scientific manner, in compliance with all Applicable Law in all material respects, including, where applicable, cGLP and current international regulatory standards; and (b) will not employ or use any Debarred Person.
Conduct of Research Activities. During the Research Term, the Parties will collaborate to conduct research in accordance with the Research Plan for each Project. The principal goals of such Collaboration will be: (a) selecting any Additional Projects and developing multiplex gene expression (MGE) and functional cell assays for use in high throughput screening of compounds for any such selected Additional Projects (the “Disease Selection Phase”), (b) identifying and discovering Active Compounds for each Project among the PTI Contributed Compounds and the Astellas Contributed Compounds through the use of high throughput screening and synthesizing and screening New Compounds for efficacy on the Primary Indication for each Project, as well as testing in the Exploratory Indications (the “HTS Phase”), and (c) characterizing, optimizing, and supporting the progression of Active Compounds identified during the HTS Phase and designated as Hit Series or synthesized after the HTS Phase into pre-clinical development as Development Compounds (the “Optimization Phase” and together with the Disease Selection Phase and the HTS Phase, the “Research Phase”, each as described in more detail in this Agreement). [***] The principal goals of each phase for each Project will be defined in a mutually agreed Research Plan. The Research Plan for the Initial Project, including the associated Research Budget, is attached hereto as Exhibit A and covers the entire Research Term. In the event that Astellas specifies one or more Additional Projects pursuant to Section 2.2 (Project Selection; Research Term Extension), the Parties will prepare and mutually agree upon the Research Plan and associated Research Budget for each such Additional Project. The JRC will update each Research Plan, including the associated Research Budget, every six (6) months during the Research Term as necessary, in accordance with Section 5.2(b)(iv) (Responsibilities of the JRC). CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. Confidential
Conduct of Research Activities a) Each of GSK and TIGET will use their respective Commercially Reasonable Efforts to conduct the activities (the “Research”), as agreed between the Parties, *** Confidential Treatment Requested *** for the purpose of achieving the specific research goals set forth in Exhibit A, attached hereto and incorporated herein by reference (the “Research Goals”). TIGET will propose to GSK those specific Research activities to be conducted by TIGET and/or by GSK with respect to the Research and will in good faith consider the reasonable comments and input of GSK with respect to the design and conduct of such activities. TIGET agrees to provide and will provide to GSK within a reasonable time access to the TIGET Methodologies. TIGET therefore hereby grants to GSK a non-exclusive, fully paid-up, royalty-free, sub-licenseable right and license under the TIGET Methodologies (provided however that with respect to such TIGET Methodologies that are not owned exclusively by TIGET, such right and license is granted to the extent TIGET has the legal right to grant such license). Each Party also grants to the other Party a non-exclusive, fully paid-up, royalty-free, worldwide, sublicenseable right and license for any and all purposes under its interest (under the following Section 3) in the methods, processes and tests arising from the conduct of the Research.
Conduct of Research Activities. Each Party will conduct and use Commercially Reasonable Efforts to complete the Research Activities allocated to it under the Research Plan. Each Party will, and will require its Affiliates and subcontractors to, perform its obligations under the Research Plan in compliance with Applicable Law.
Conduct of Research Activities. Following approval of each Research Plan as set forth in Section 3.2, with respect to each Research Plan, MeiraGTx will use Commercially Reasonable Efforts to perform (itself or through its Affiliates or subject to Section 4.4, permitted subcontractors) the Research Plan Activities associated with such Research Plan in accordance with the applicable Research Plan (including the timelines set forth therein) for the duration of the Research Plan Term. In performing its respective Research Plan Activities, MeiraGTx: (a) will conduct such activities in a good scientific manner and in compliance with all Applicable Laws in all material respects, including, where applicable, cGMP, cGLP, cGCP, good pharmacovigilance practices and current international regulatory standards; (b) will not employ or use any Debarred Person; and (c) will not use any MeiraGTx [***] Technology during the course of performing Research Plan Activities or incorporate any MeiraGTx [***] Technology into any Research IRD Product [***].
